中文 
别名:FAE; FACE应用:IHC
反应种属:Human
规格：50μl/100μl
| Description |
|---|
| The Fanconi anemia complementation group (FANC) currently includes FANCA, FANCB, FANCC, FANCD1 (also called BRCA2), FANCD2, FANCE, FANCF, FANCG, FANCI, FANCJ (also called BRIP1), FANCL, FANCM and FANCN (also called PALB2). The previously defined group FANCH is the same as FANCA. Fanconi anemia is a genetically heterogeneous recessive disorder characterized by cytogenetic instability, hypersensitivity to DNA crosslinking agents, increased chromosomal breakage, and defective DNA repair. The members of the Fanconi anemia complementation group do not share sequence similarity; they are related by their assembly into a common nuclear protein complex. This gene encodes the protein for complementation group E. |
| Specification | |
|---|---|
| Aliases | FAE; FACE |
| Swissprot | Q9HB96 |
| Host/Isotype | Rabbit IgG |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human FANCE |
| Formulation | pH7.4 PBS, 0.05% NaN3, 40% Glycerol |
| Application | |
|---|---|
| IHC | 1/40-1/200 |
| ELISA | 1/5000-1/10000 |
 |
The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P06504(FANCE Antibody) at dilution 1/50. (Original magnification: ×200) |
本公司的所有产品仅用于科学研究或者工业应用等非医疗目的，不可用于人类或动物的临床诊断或治疗，非药用，非食用。
暂无评论
本公司的所有产品仅用于科学研究或者工业应用等非医疗目的，不可用于人类或动物的临床诊断或治疗，非药用，非食用。
发表回复